OTC Markets OTCPK - Delayed Quote USD

Swedish Orphan Biovitrum AB (publ) (SWOBY)

Compare
15.00 0.00 (0.00%)
As of December 16 at 3:00:00 PM EST. Market Open.
Currency in SEK All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
25,435,000.00
22,123,000.00
18,790,000.00
15,529,000.00
15,261,000.00
Cost of Revenue
5,573,000.00
4,995,000.00
4,776,000.00
3,484,000.00
3,225,000.00
Gross Profit
19,863,000.00
17,128,000.00
14,014,000.00
12,045,000.00
12,036,000.00
Operating Expense
14,174,000.00
12,948,000.00
10,169,000.00
8,258,000.00
7,573,000.00
Operating Income
5,689,000.00
4,180,000.00
3,845,000.00
3,787,000.00
4,463,000.00
Net Non Operating Interest Income Expense
-1,390,000.00
-1,135,000.00
-481,000.00
-454,000.00
-486,000.00
Pretax Income
4,206,000.00
2,954,000.00
3,321,000.00
3,295,000.00
4,217,000.00
Tax Provision
693,000.00
546,000.00
683,000.00
616,000.00
972,000.00
Net Income Common Stockholders
3,514,000.00
2,409,000.00
2,638,000.00
2,679,000.00
3,245,000.00
Diluted NI Available to Com Stockholders
3,514,000.00
2,409,000.00
2,638,000.00
2,679,000.00
3,245,000.00
Basic EPS
5.17
3.73
4.26
4.34
5.26
Diluted EPS
5.11
3.69
4.22
4.31
5.21
Basic Average Shares
688,650.40
645,317.79
618,955.24
617,797.07
616,974.22
Diluted Average Shares
696,710.69
651,935.30
624,910.47
621,457.86
623,218.20
Total Operating Income as Reported
5,573,000.00
4,066,000.00
3,813,000.00
3,733,000.00
4,818,000.00
Total Expenses
19,747,000.00
17,943,000.00
14,945,000.00
11,742,000.00
10,798,000.00
Net Income from Continuing & Discontinued Operation
3,514,000.00
2,409,000.00
2,638,000.00
2,679,000.00
3,245,000.00
Normalized Income
3,514,835.24
2,409,815.00
2,638,000.00
2,724,530.80
2,939,707.00
Interest Income
--
27,000.00
5,000.00
--
1,000.00
Interest Expense
--
1,111,000.00
458,000.00
419,000.00
454,000.00
Net Interest Income
-1,390,000.00
-1,135,000.00
-481,000.00
-454,000.00
-486,000.00
EBIT
5,574,000.00
4,065,000.00
3,779,000.00
3,714,000.00
4,671,000.00
EBITDA
9,253,000.00
7,234,000.00
6,051,000.00
5,720,000.00
6,694,000.00
Reconciled Cost of Revenue
5,573,000.00
4,995,000.00
4,776,000.00
3,484,000.00
3,225,000.00
Reconciled Depreciation
3,679,000.00
3,169,000.00
2,272,000.00
2,006,000.00
2,023,000.00
Net Income from Continuing Operation Net Minority Interest
3,514,000.00
2,409,000.00
2,638,000.00
2,679,000.00
3,245,000.00
Total Unusual Items Excluding Goodwill
-1,000.00
-1,000.00
--
-56,000.00
397,000.00
Total Unusual Items
-1,000.00
-1,000.00
--
-56,000.00
397,000.00
Normalized EBITDA
9,254,000.00
7,235,000.00
6,051,000.00
5,776,000.00
6,297,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-164.76
-185.00
--
-10,469.20
91,707.00
12/31/2020 - 10/2/2023

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VYYRF Voyageur Pharmaceuticals Ltd.
0.0020
0.00%
 
OWPC One World Products, Inc.
0.0194
-1.52%
 
ROMJF Rubicon Organics Inc.
0.2730
0.00%
 
CBDL CBD Life Sciences Inc.
0.0004
0.00%
 
AKAN Akanda Corp.
1.3500
-2.88%
 
CBSTF The Cannabist Company Holdings Inc.
0.0501
-8.91%
 
AYRWF Ayr Wellness Inc.
0.4300
+8.86%
 
VRNOF Verano Holdings Corp.
1.2200
0.00%
 
OGI Organigram Holdings Inc.
1.6100
+5.23%
 
BIOA BioAge Labs, Inc.
4.2050
+1.57%